Xin Lang Cai Jing·2025-09-09 02:09Core Viewpoint - The innovative drug concept is gaining momentum, with Rongchang Biopharmaceuticals experiencing a significant stock increase of over 15%, reaching a historical high, following the acceptance of its drug application for a novel treatment for Sjögren's syndrome [1] Company Summary - Rongchang Biopharmaceuticals announced that its self-developed innovative drug, a first-in-class BLyS/APRIL dual-target fusion protein named Tai Tasi Pu, has received formal acceptance from the National Medical Products Administration (NMPA) for its market application [1] - This drug application marks the first-ever submission for a biological drug in the Sjögren's syndrome field globally [1] Industry Summary - The innovative drug sector is experiencing a strong upward trend, with several companies such as Yipinhong, Baiji Shenzhou, Junshi Biosciences, Xin Nuo Wei, and Rejing Biopharmaceuticals also seeing stock price increases alongside Rongchang Biopharmaceuticals [1]